MedDataX Logo

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

NCT ID: NCT00704912

Last Updated: 2016-11-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

217 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this three-armed randomized controlled trial is to establish the relative roles of treatment of hyperandrogenism versus obesity (as the largest modifiable factor contributing to insulin resistance) in treating infertility and improving pregnancy outcomes among obese PCOS women. The investigators hypothesize that the key to restoring ovulation leading to live birth is to correct hyperandrogenism with oral contraceptive pills, but the key to avoiding later pregnancy complications is to improve insulin sensitivity with weight loss.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility among women, and women with PCOS are at increased risk for pregnancy complications such as gestational diabetes and pre-eclampsia. Both hyperandrogenism (HA) and obesity exacerbated insulin resistance (IR) are characteristics of the syndrome, and are targets for treatment, but which should be the predominant focus is still unknown. Phase 1 of this study will be a randomized trial of three preconception interventions in infertile women with PCOS. The first arm will be a combined intervention of medication, meal replacements, and lifestyle modification to improve IR. Orlistat is a gastric lipase inhibitor that reduces the absorption of fat contained in a meal by about 30%. The second arm will be the use of a continuous OCP for 4 months to improve HA. Lo-Estrin 1/20 will be used in a continuous method for 4 months to suppress the ovary. The third arm is the combination of both to improve HA an IR. Phase II of this study will involve ovulation induction with clomiphene citrate with hopeful outcome of pregnancy. Finally, Phase III involve following the pregnancies for outcomes and complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Polycystic Ovary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lifestyle intervention

Orlistat/Meal Replacement/Lifestyle Modification

Group Type ACTIVE_COMPARATOR

Orlistat/Meal Replacement/Lifestyle Modification

Intervention Type DRUG

Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.

Oral Contraceptives (OCP)

Loestrin 1/20

Group Type ACTIVE_COMPARATOR

Loestrin 1/20

Intervention Type DRUG

Patients will be started on a low dose containing OCP for a continuous 4 month period.

Lifestyle/OCP Combined

Combination of treatments

Group Type ACTIVE_COMPARATOR

Combination of treatments

Intervention Type DRUG

Medications will be administered as described for the other 2 arms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Orlistat/Meal Replacement/Lifestyle Modification

Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.

Intervention Type DRUG

Loestrin 1/20

Patients will be started on a low dose containing OCP for a continuous 4 month period.

Intervention Type DRUG

Combination of treatments

Medications will be administered as described for the other 2 arms.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Orlistat Alli Lifestyle Intervention Weight Loss OCP Oral Contraceptive Orlistat Alli OCP Oral Contraceptive Weight Loss Lifestyle Intervention

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Partner with sperm concentration of \>=14 million/mL in at least one ejaculate with motile sperm.
* Ability to have regular intercourse 2-3 times per week during the ovulation induction phase of study.
* At least one patent tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years, or confirmation of a intrauterine pregnancy within the past 2 years.
* No previous sterilization procedures(vasectomy, tubal ligation) that have been reversed.
* Wanting to seek pregnancy.


* Chronic anovulation or oligomenorrhea defined as intermenstrual periods of \>= 45 days or a total of \<=8 periods per year.
* Hyperandrogenism will be an elevated total testosterone \>=50 ng/dL.
* Hirsutism determined by a modified Ferriman-Gallwey Score \>8.
* PCO on ultrasound (12 or more follicles measuring 2-9 mm in diameter).
* BMI \>=27 to \<=42.
* Normal EKG to rule out any abnormalities with the heart.

Exclusion Criteria

* Current pregnancy.
* Patients on oral contraceptives, depo progestins, or hormonal implants.
* Patients with hyperprolactinemia defined as two prolactin levels at least one week apart \>30 ng/mL.
* Patients with known 21-hydroxylase deficiency by a fasting 17-hydroxyprogesterone (17-OHP) level \<2 ng/mL and ACTH stimulation test as needed, or other enzyme deficiency.
* Patients with menopausal FSH levels \>20 mIU/mL.
* Patients with uncorrected thyroid disease (TSH \<0.45 mIU/ML or \>4.5 mIU/ML).
* Patients diagnosed with Type1 or Type II diabetes.
* Patients with liver disease defined as AST or ALT \>2 times normal or total bilirubin \>2.5 mg/dL.
* Patients with renal disease defined as BUN \>30 mg/dL or serum creatinine \>1.4 mg/dL.
* Patients with significant anemia (Hemoglobin \<10 mg/dL).
* Patients with a history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
* Patients with known heart disease that is likely to be exacerbated by pregnancy.
* Patients with a history of , or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma. A normal PAP smear or reassuring colposcopy based on current ACOG guidelines will be required.
* Patient with current history of alcohol abuse.
* Patients enrolled simultaneously into other investigative studies.
* Patients taking other medications know to affect reproductive function or metabolism.
* Patients with a suspected adrenal or ovarian tumor secreting androgens.
* Patients with suspected Cushing's syndrome.
* Patients who have undergone a bariatric surgery procedure in the recent past (\<12 months).
* Patients with untreated poorly controlled hypertension defined as systolic blood pressure \>=150 mm Hg or average diastolic \>=100 mm Hg on three measurements obtained 5 minutes apart. If treated, average systolic blood pressure \>= 140 mm Hg or average diastolic \>= 90 mm Hg.
* Patients with medical conditions that represent contraindications to orlistat, OCP, clomiphene, and/or pregnancy.
* Patients currently participating in lifestyle intervention program (Weight Watchers, Atkins Diet, Curves) or lost more than 5% body weight within the last 6 months.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pennsylvania

OTHER

Sponsor Role collaborator

Milton S. Hershey Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Richard S. Legro, M.D.

Professor, Obstetrics and Gynecology and Public Health Sciences

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard S Legro, M.D.

Role: PRINCIPAL_INVESTIGATOR

Penn State College of Medicine, Penn State Milton S. Hershey Medical Center

Christos Coutifaris, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Universtiy of Pennsylvania, Department of Obstetrics and Gynecology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Penn State College of Medicine, Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

University of Pennsylvania, Department of Obstetrics and Gynecology

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Steinberg Weiss M, Roe AH, Allison KC, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Sarwer DB, Coutifaris C, Legro RS, Dokras A. Lifestyle modifications alone or combined with hormonal contraceptives improve sexual dysfunction in women with polycystic ovary syndrome. Fertil Steril. 2021 Feb;115(2):474-482. doi: 10.1016/j.fertnstert.2020.08.1396. Epub 2020 Oct 12.

Reference Type DERIVED
PMID: 33059886 (View on PubMed)

Shah A, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Gnatuk CL, Estes SJ, Allison KC, Sarwer DB, Sluss PM, Coutifaris C, Dokras A, Legro RS. Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ss Superfamily Hormones in PCOS. J Clin Endocrinol Metab. 2021 Jan 1;106(1):108-119. doi: 10.1210/clinem/dgaa682.

Reference Type DERIVED
PMID: 32968804 (View on PubMed)

Dokras A, Sarwer DB, Allison KC, Milman L, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Fleming J, Coutifaris C, Legro RS. Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS. J Clin Endocrinol Metab. 2016 Aug;101(8):2966-74. doi: 10.1210/jc.2016-1896. Epub 2016 Jun 2.

Reference Type DERIVED
PMID: 27253669 (View on PubMed)

Legro RS, Dodson WC, Kunselman AR, Stetter CM, Kris-Etherton PM, Williams NI, Gnatuk CL, Estes SJ, Allison KC, Sarwer DB, Diamond MP, Schlaff WD, Casson PR, Christman GM, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Zhang H, Eisenberg E, Coutifaris C, Dokras A. Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS. J Clin Endocrinol Metab. 2016 Jul;101(7):2658-66. doi: 10.1210/jc.2016-1659. Epub 2016 May 12.

Reference Type DERIVED
PMID: 27172435 (View on PubMed)

Legro RS, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ, Fleming J, Allison KC, Sarwer DB, Coutifaris C, Dokras A. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2015 Nov;100(11):4048-58. doi: 10.1210/jc.2015-2778. Epub 2015 Sep 24.

Reference Type DERIVED
PMID: 26401593 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.hmc.psu.edu

Click here for more information about this study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

27184

Identifier Type: -

Identifier Source: org_study_id